focus -WSS

focus

author：comprehensive 2025-09-06 09:29:53 Page View：5557

close-up of psoriasis on a hand. -- biotech coverage from STAT — A close-up of psoriasis on a hand. Adobe

San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wearables generate powerful data but its not useful to doctors, yet
Next article： Heart attack and stroke risk calculators need revising

explore

Affirmative action in medical school literally saved lives

AdobeThepastseveralmonthshavebeengrimforhealthintheU.S.InDecember,theCentersforDiseaseControlandPrev

Addiction experts warn against a second 'war on drugs'

STAT'sLevFacher(left)spokewiththreeaddictionexperts—(fromleft)BraunzCourtney,KeithHumphreys,andAyesh

Tori Bowie and the unacceptable rates of Black maternal death

AlastairGrant/APThehorrorstoriesofBlackwomendyingorcomingclosetodeathinchildbirthneverseemtostopcomi

Second House panel advances two

Rep.CathyMcMorrisRodgers(R-Wash.)chairsaHousepanelthatadvancedtelehealthlegislation.SusanWalsh/APWAS

focus

leisure time

explore

Second House panel advances two